Do analysts rate NXL or TELA?

TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 214.29%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is NXL or TELA more profitable?

TELA Bio has a net margin of -51.53% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nexalin Technology -4,141.94% -278.24% -218.42% TELA Bio -51.53% -1,320.81% -59.39%

Do analysts rate BEAT or NXL?

HeartBeam presently has a consensus target price of $4.00, indicating a potential upside of 756.71%. Given HeartBeam's stronger consensus rating and higher probable upside, equities analysts plainly believe HeartBeam is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartBeam 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend NXL or PETV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXL or PETV more profitable?

PetVivo has a net margin of -902.82% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Nexalin Technology -4,141.94% -278.24% -218.42% PetVivo -902.82% -4,813.07% -281.78%

Do analysts recommend NXL or CTSO?

Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,501.61%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend NXL or LFWD?

Lifeward has a consensus target price of $10.00, suggesting a potential upside of 34.05%. Given Lifeward's stronger consensus rating and higher probable upside, analysts plainly believe Lifeward is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifeward 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media favor NXL or LFWD?

In the previous week, Lifeward had 7 more articles in the media than Nexalin Technology. MarketBeat recorded 13 mentions for Lifeward and 6 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.31 beat Lifeward's score of -0.09 indicating that Nexalin Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifeward 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nexalin Technology (NXL) Competitors

$0.25 0.00 (-1.88%)

As of 08/28/2026 04:00 PM Eastern

Compare

NXL vs. TELA, BEAT, PETV, CTSO, and LFWD

Should you buy Nexalin Technology stock or one of its competitors? Nexalin Technology's main competitors and comparable companies include TELA Bio (TELA), HeartBeam (BEAT), PetVivo (PETV), Cytosorbents (CTSO), and Lifeward (LFWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nexalin Technology compare to TELA Bio?

Nexalin Technology (NASDAQ:NXL) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Nexalin Technology has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	18.37	-$8.22M	-$0.48	N/A
TELA Bio	$80.28M	0.39	-$38.83M	-$0.77	N/A

Nexalin Technology has a beta of 4, indicating that its share price is 300% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 214.29%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by insiders. Comparatively, 5.1% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TELA Bio has a net margin of -51.53% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
TELA Bio	-51.53%	-1,320.81%	-59.39%

In the previous week, Nexalin Technology had 5 more articles in the media than TELA Bio. MarketBeat recorded 6 mentions for Nexalin Technology and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 1.89 beat Nexalin Technology's score of 0.31 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Nexalin Technology	Neutral
TELA Bio	Very Positive

Summary

Nexalin Technology and TELA Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to HeartBeam?

HeartBeam (NASDAQ:BEAT) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nexalin Technology has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
Nexalin Technology	$300K	18.37	-$8.22M	-$0.48	N/A

HeartBeam has a beta of -0.78, suggesting that its stock price is 178% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, suggesting that its stock price is 300% more volatile than the broader market.

HeartBeam has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

In the previous week, Nexalin Technology had 5 more articles in the media than HeartBeam. MarketBeat recorded 6 mentions for Nexalin Technology and 1 mentions for HeartBeam. HeartBeam's average media sentiment score of 1.89 beat Nexalin Technology's score of 0.31 indicating that HeartBeam is being referred to more favorably in the media.

Company	Overall Sentiment
HeartBeam	Very Positive
Nexalin Technology	Neutral

HeartBeam presently has a consensus target price of $4.00, indicating a potential upside of 756.71%. Given HeartBeam's stronger consensus rating and higher probable upside, equities analysts plainly believe HeartBeam is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

HeartBeam and Nexalin Technology tied by winning 8 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to PetVivo?

Nexalin Technology (NASDAQ:NXL) and PetVivo (NASDAQ:PETV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Nexalin Technology had 6 more articles in the media than PetVivo. MarketBeat recorded 6 mentions for Nexalin Technology and 0 mentions for PetVivo. Nexalin Technology's average media sentiment score of 0.31 beat PetVivo's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Nexalin Technology	Neutral
PetVivo	Neutral

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nexalin Technology has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	18.37	-$8.22M	-$0.48	N/A
PetVivo	$1.05M	24.67	-$10.95M	-$0.34	N/A

Nexalin Technology has a beta of 4, indicating that its share price is 300% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PetVivo has a net margin of -902.82% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
PetVivo	-902.82%	-4,813.07%	-281.78%

Summary

Nexalin Technology beats PetVivo on 9 of the 14 factors compared between the two stocks.

How does Nexalin Technology compare to Cytosorbents?

Nexalin Technology (NASDAQ:NXL) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

In the previous week, Nexalin Technology had 5 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for Nexalin Technology and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Nexalin Technology's score of 0.31 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Overall Sentiment
Nexalin Technology	Neutral
Cytosorbents	Very Positive

Nexalin Technology has a beta of 4, meaning that its stock price is 300% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Cytosorbents has a net margin of -48.94% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
Cytosorbents	-48.94%	-431.65%	-41.94%

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,501.61%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytosorbents has higher revenue and earnings than Nexalin Technology. Cytosorbents is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	18.37	-$8.22M	-$0.48	N/A
Cytosorbents	$37.06M	0.57	-$8.20M	-$0.29	N/A

Summary

Cytosorbents beats Nexalin Technology on 10 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to Lifeward?

Nexalin Technology (NASDAQ:NXL) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Lifeward had 7 more articles in the media than Nexalin Technology. MarketBeat recorded 13 mentions for Lifeward and 6 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.31 beat Lifeward's score of -0.09 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifeward	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by insiders. Comparatively, 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nexalin Technology has higher earnings, but lower revenue than Lifeward. Nexalin Technology is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	18.37	-$8.22M	-$0.48	N/A
Lifeward	$22.03M	0.96	-$19.91M	-$16.82	N/A

Nexalin Technology has a beta of 4, meaning that its share price is 300% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Lifeward has a consensus target price of $10.00, suggesting a potential upside of 34.05%. Given Lifeward's stronger consensus rating and higher probable upside, analysts plainly believe Lifeward is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifeward	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Lifeward has a net margin of -141.28% compared to Nexalin Technology's net margin of -4,141.94%. Lifeward's return on equity of -235.86% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
Lifeward	-141.28%	-235.86%	-81.72%

Summary

Lifeward beats Nexalin Technology on 10 of the 16 factors compared between the two stocks.

Get Nexalin Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXL vs. The Competition

Export

Metric	Nexalin Technology	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.51M	$5.88B	$7.21B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-0.52	25.92	273.16	25.42
Price / Sales	18.37	69.46	629.76	95.09
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	1.25	6.18	11.08	6.36
Net Income	-$8.22M	$149.94M	$3.48B	$349.79M
7 Day Performance	-24.72%	-0.24%	0.13%	-0.80%
1 Month Performance	-26.90%	6.18%	7.08%	4.13%
1 Year Performance	-73.86%	6.30%	24.67%	15.17%

Nexalin Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXL Nexalin Technology	0.4151 of 5 stars	$0.25 -1.9%	N/A	-73.9%	$5.51M	$300K	N/A	3	News Coverage Negative News Upcoming Earnings
TELA TELA Bio	3.7206 of 5 stars	$0.64 -1.1%	$2.20 +242.1%	-60.7%	$28.93M	$80.28M	N/A	120	Positive News Gap Up High Trading Volume
BEAT HeartBeam	2.4361 of 5 stars	$0.48 -4.0%	$4.00 +733.2%	-65.5%	$27.72M	N/A	N/A	1,700	Positive News
PETV PetVivo	N/A	$0.68 -0.7%	N/A	N/A	$25.72M	$1.05M	N/A	20	High Trading Volume
CTSO Cytosorbents	2.6175 of 5 stars	$0.36 -4.6%	$5.38 +1,393.1%	-64.4%	$23.70M	$37.22M	N/A	220	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXL) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nexalin Technology (NXL) Competitors

NXL vs. TELA, BEAT, PETV, CTSO, and LFWD

How does Nexalin Technology compare to TELA Bio?

Summary

How does Nexalin Technology compare to HeartBeam?

Summary

How does Nexalin Technology compare to PetVivo?

Summary

How does Nexalin Technology compare to Cytosorbents?

Summary

How does Nexalin Technology compare to Lifeward?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nexalin Technology (NXL) Competitors

NXL vs. TELA, BEAT, PETV, CTSO, and LFWD

How does Nexalin Technology compare to TELA Bio?

Which has better earnings and valuation, NXL or TELA?

Which has more risk and volatility, NXL or TELA?

Do analysts rate NXL or TELA?

Do institutionals & insiders believe in NXL or TELA?

Is NXL or TELA more profitable?

Does the media prefer NXL or TELA?

Summary

How does Nexalin Technology compare to HeartBeam?

Do institutionals & insiders have more ownership in BEAT or NXL?

Which has stronger valuation and earnings, BEAT or NXL?

Which has more volatility & risk, BEAT or NXL?

Is BEAT or NXL more profitable?

Does the media favor BEAT or NXL?

Do analysts rate BEAT or NXL?

Summary

How does Nexalin Technology compare to PetVivo?

Does the media prefer NXL or PETV?

Do institutionals & insiders hold more shares of NXL or PETV?

Which has better valuation and earnings, NXL or PETV?

Which has more volatility & risk, NXL or PETV?

Do analysts recommend NXL or PETV?

Is NXL or PETV more profitable?

Summary

How does Nexalin Technology compare to Cytosorbents?

Does the media refer more to NXL or CTSO?

Which has more volatility & risk, NXL or CTSO?

Is NXL or CTSO more profitable?

Do institutionals & insiders hold more shares of NXL or CTSO?

Do analysts recommend NXL or CTSO?

Which has preferable earnings & valuation, NXL or CTSO?

Summary

How does Nexalin Technology compare to Lifeward?

Does the media favor NXL or LFWD?

Do insiders & institutionals have more ownership in NXL or LFWD?

Which has higher earnings and valuation, NXL or LFWD?

Which has more risk and volatility, NXL or LFWD?

Do analysts recommend NXL or LFWD?

Is NXL or LFWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools